Research from Centre Leon Berard in Chronic Myeloid Leukemia Provides New Insights [Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in "Real-Life" Settings: A...].

A recent study conducted in France provides new insights into the treatment patterns of chronic myeloid leukemia (CML) patients using tyrosine kinase inhibitors (TKIs). The study, which analyzed data from over 5,000 CML patients, found that one in five patients received at least three lines of TKI treatment due to resistance or adverse events. The study also revealed that TKI switches are common, with around half of the switches occurring within the first two years of treatment. The findings highlight the need for ongoing care and alternative treatment options for CML patients to improve their long-term outcomes. [Extracted from the article]